However, until everyone can benefit from this medication, with equal access – irrespective of postcode or budget, their success will be limited, warns British Dietetic Association.
In a joint position statement by the British Dietetic Association (BDA) and the British Nutrition Foundation (BNF), the prescribed use of GLP-1/ GIP Receptor Agonists for people living with obesity and/or type 2 diabetes has been broadly supported. However, concerns have been raised about how the people that need them most are able to access them safely and if they are being given the ongoing support they need, to achieve long-term results.